Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer

Table 2

Clinicopathological features and expression of TSP50 protein for prognosis of 334 patients with gastric cancers by univariate survival analysis (log-rank test).

Clinicopathological features	All cases	Mean ± SE^a	Median ± SE	𝑃 value
Gender
Male	233	35.66±1.87	40.00±8.07	0.053
Female	101	28.83±2.59	19.00±2.12
Age at surgery
≥57	172	32.34±2.14	27.00±5.63	0.312
<57	162	35.16±2.20	30.00±11.72
Tumor size
≥5 cm	149	31.42±2.21	20.00±3.23	0.289
<5 cm	185	35.35±2.11	40.00±6.83
Histological type
Intestinal	265	35.04±1.68	30.00±5.15	0.006
Diffuse	69	24.81±3.22	13.00±2.22
TNM
I + II	117	52.14±2.15	NR^b	0.000
III + IV	217	24.73±1.64	16.00±1.29
Lymph node metastases
Present	234	25.73±1.61	17.00±1.31	0.003
Absent	100	54.34±1.53	27.00±4.70
TSP50 protein expression
Low	143	38.02±2.36	40.00±9.11	0.021
High	191	30.21±1.97	19.00±2.32

aSE: standard error; bNR: not reach.